A global ayahuasca survey has found 70% experience physical and 55% mental health adverse effects, but only 2.3% of participants reporting physical adverse events required medical...
Tryp has announced interim data for the first five patients dosed in its Phase 2 trial, stating the data supports the potential effectiveness of psilocybin-assisted psychotherapy...
The nonprofit Multidisciplinary Association for Psychedelic Studies’ (MAPS) has announced its clinical research programme has had a successful confirmatory Phase 3 trial of MDMA-assisted therapy for...
Tryp Therapeutics and MGH will fund and conduct a Phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients suffering from...
Algernon Pharmaceuticals (AGN Pharma) has established Algernon NeuroScience (AGN Neuro), a new wholly-owned private subsidiary of AGN Pharma, to advance its DMT stroke programme.
A new study, led by University of California – Riverside (UCR) doctoral ethnomusicology student Owain J.
The Psychedelics as Medicine Report has revealed the industry is currently worth US$650 million (~£542 million), and is expected to exceed US$3 billion by 2026.
The therapeutic benefits of many psychedelics have been clearly demonstrated through clinical trials, where the use of psilocybin-, ketamine-, and MDMA-assisted psychotherapy showed striking long-term improvements...
The Psychedelic Access and European Alliance (PAREA) has launched an appeal to European Union institutions and Member States for psychedelic-assisted therapies in Europe.
Awakn Life Sciences has announced that its Phase III clinical trial exploring the use of ketamine-assisted therapy for the treatment of severe alcohol use disorder (AUD)...